Navigation Links
BioMarin to Present at the Wedbush Life Sciences Conference
Date:8/9/2011

NOVATO, Calif., Aug. 9, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wedbush Life Sciences Conference in New York on Tuesday, August 16, 2011 at 10:00 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical developmen
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioMarin Announces Second Quarter 2011 Financial Results
2. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
3. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
4. BioMarin to Present at the William Blair Growth Stock Conference
5. BioMarin to Present at the Jefferies Global Healthcare Conference
6. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
7. BioMarin Announces First Quarter 2011 Financial Results
8. BioMarin to Present at the Deutsche Bank Healthcare Conference
9. BioMarin to Present at the Barclays Global Healthcare Conference
10. BioMarin to Present at the Cowen Health Care Conference
11. BioMarin to Present at the Citi Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Inc.,(Nasdaq: MEDX ) today announced interim ... an investigational oncology immunotherapy, as monotherapy or ... castration,resistant prostate cancer (mCRPC). Data presented showed ... was clinically active and,generally well-tolerated. Preliminary evidence ...
... and REGENSBURG, Germany, June 2 "A ... in recurrent or refractory anaplastic,astrocytoma suggests a ... commented Prof. Ulrich Bogdahn, Neuro-Oncologist and Coordinating,Investigator ... with AP,12009 in recurrent or refractory high-grade ...
Cached Medicine Technology:Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 2Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 3Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting 4Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4
(Date:4/17/2014)... 2014 Giving patients adrenaline after they suffer a cardiac ... prospects of surviving long-term, according to new research conducted ... patients who have a cardiac arrest get adrenaline, which ... for decades," said Dr. Steve Lin, an emergency physician ... advances in medical treatment, long-term survival rates of patients ...
(Date:4/17/2014)... LSTM have called for more research to be ... children in sub-Saharan Africa. In a paper in ... Russell Stothard, working with colleagues in the department ... University, in Cleveland Ohio, University of Cambridge and ... into the joint burden of HIV/AIDS and schistosomiasis ...
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that final ... solid tumors, including long-term patient follow-up, have been published ... 232). The data demonstrate robust antibody and T cell ... very advanced cancers and suggest that CDX-1401 may predispose ...
(Date:4/16/2014)... it is well known that fertility treatments are the ... multiples are at elevated risk of premature birth, these ... Fertility and Sterility . The article identifies ... the odds of multiple births and prematurity, including expanding ...
(Date:4/15/2014)... , , CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... way to fight invasive fungal infections, which kill about 1.5 million ... of action of amphotericin, an antifungal drug that has been in ... nearly as toxic to human cells as it is to the ...
Breaking Medicine News(10 mins):Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... BMR, TORONTO, Dec. 12 /PRNewswire-FirstCall/ - Bradmer ... and,commercialization of cancer therapies, today announced that Keith ... to join the Company,s Scientific,Advisory Board. Dr. Black ... America, having performed more than 5,000 operations for ...
... Patient organizations support extending MSP and using savings ... American Kidney Fund and DaVita Patient Citizens submit ... WASHINGTON, Dec. 12 -Kidney Care Partners --,a ... manufacturers working together to improve quality of care ...
... Asia, Africa may not apply to patients in the ... Disappointing the hopes of researchers, new trials using a ... little or no benefit from the drugs. , "It ... lecturer in infectious diseases at the University of Malawi ...
... movies and TV shows make light of womens so-called ... or, conversely, to menopause. In fact, mood disorders are ... studies have found women are 1.5 to 3 times ... are men. , In a newly published study, ...
... Scient,x USA, an innovative,leader in the development and marketing ... today that Bryce T. IntVeld has,joined the Company as ... provide leadership and oversee the establishment and expansion,of sales ... delighted to have Bryce as a member of our ...
... WASHINGTON, Dec. 12 The Long Term Care,Pharmacy ... policy voice,for pharmacies which specifically serve nursing home ... its membership to include LTC pharmacy,companies that serve ... living in 47 states., "LTCPA represents highly ...
Cached Medicine News:Health News:Bradmer announces additions to Scientific Advisory Board 2Health News:Bradmer announces additions to Scientific Advisory Board 3Health News:Kidney Patient Organizations, Kidney Community Come Out in Support of Medicare Secondary Payer (MSP) Extension 2Health News:Kidney Patient Organizations, Kidney Community Come Out in Support of Medicare Secondary Payer (MSP) Extension 3Health News:Steroid Fails to Ease Meningitis in Trials 2Health News:Steroid Fails to Ease Meningitis in Trials 3Health News:Experts call for better research into link between women's hormones and mood disorders 2Health News:Scient'x USA Strengthens Leadership Team With Appointment of Bryce IntVeld as Vice President of Sales 2Health News:Long Term Care Pharmacy Alliance Expands Membership; Members Now Serve Most of the Nation's Nursing Home Residents 2
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
The First Aid for the Surgery Clerkship is designed to prepare for the surgery clerkship examination and provides clinical diagnosis and treatment of many of the problems seen by surgeons....
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician....
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
Medicine Products: